Avidity Biosciences (RNA) Competitors

Avidity Biosciences (NASDAQ:RNA) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership.

Does the MarketBeat Community prefer RNA or GMAB?

Genmab A/S received 6 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 67.81% of users gave Avidity Biosciences an outperform vote while only 62.84% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Avidity Biosciences	Outperform Votes 158 67.81%	Underperform Votes 75 32.19%
Genmab A/S	Outperform Votes 164 62.84%	Underperform Votes 97 37.16%

Which has more risk and volatility, RNA or GMAB?

Avidity Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Genmab A/S has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of RNA or GMAB?

7.1% of Genmab A/S shares are owned by institutional investors. 3.7% of Avidity Biosciences shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Is RNA or GMAB more profitable?

Genmab A/S has a net margin of 36.30% compared to Avidity Biosciences' net margin of -2,772.45%. Genmab A/S's return on equity of 16.78% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-2,772.45%	-27.66%	-24.56%
Genmab A/S	36.30%	16.78%	13.79%

Which has preferable earnings and valuation, RNA or GMAB?

Genmab A/S has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$9.56M	403.98	-$212.22M	-$2.88	-11.24
Genmab A/S	$3.12B	4.72	$1.14B	$1.74	12.80

Do analysts prefer RNA or GMAB?

Avidity Biosciences presently has a consensus target price of $65.80, suggesting a potential upside of 103.27%. Genmab A/S has a consensus target price of $42.17, suggesting a potential upside of 89.30%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genmab A/S	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

Does the media favor RNA or GMAB?

In the previous week, Genmab A/S had 15 more articles in the media than Avidity Biosciences. MarketBeat recorded 18 mentions for Genmab A/S and 3 mentions for Avidity Biosciences. Genmab A/S's average media sentiment score of 1.00 beat Avidity Biosciences' score of 0.85 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Avidity Biosciences on 12 of the 19 factors compared between the two stocks.